Eloralintide vs HGH Fragment 176-191
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss Agonists
EloralintideFat Loss & Metabolic
HGH Fragment 176-191- Summary
- Eloralintide is a long-acting amylin analog under development by OPKO Health. Amylin is co-secreted with insulin and regulates post-meal glucose by slowing gastric emptying, suppressing glucagon, and promoting satiety. Eloralintide is designed for once-weekly dosing, differentiating it from the short-acting pramlintide (Symlin). It is being studied for obesity and type 2 diabetes as a complement to GLP-1 based therapies.
- HGH Fragment 176-191 (also known as AOD-9604) is a stabilized, modified fragment of the human growth hormone molecule corresponding to amino acids 176–191 with an addition of a tyrosine residue at the N-terminus. It retains HGH's fat-burning properties without the anabolic, diabetogenic, or IGF-1-stimulating effects.
- Half-Life
- ~7 days (estimated, long-acting design)
- ~30 minutes
- Admin Route
- SubQ
- SubQ
- Research
- —
- —
- Typical Dose
- Under investigation in Phase 1/2 trials
- 250–500 mcg
- Frequency
- Once weekly
- 1–3 times daily
- Key Benefits
- Once-weekly dosing (vs multiple daily injections for pramlintide)
- Appetite suppression via central amylin receptor activation
- Reduction in post-meal glucagon secretion
- Complementary mechanism to GLP-1 agonists for combination therapy
- Slows gastric emptying for prolonged satiety
- Potential additive weight loss when combined with GLP-1 agents
- Selective fat burning without anabolic side effects
- Reduces visceral and subcutaneous fat
- No insulin resistance or blood glucose disruption
- Does not stimulate IGF-1
- May support cartilage and bone repair (at higher doses)
- No effect on growth or organ size
- Side Effects
- Nausea
- Vomiting
- Decreased appetite
- Injection site reactions
- +1 more
- Injection site irritation
- Temporary lethargy
- Headache (rare)
- Nausea (rare)
- Stacks With
- —
- —